Endpoints for clinical trials of sarcoidosis

Robert P. Baughmann; M. Drent; D. A. Culver; J. C. Grutiers; T. Handa; M. Humbert; M. A. Judson; E. E. Lower; J. Mana; C. A. Pereira; A. Prasse; R. Sulica; D. Valyere; V. Vucinic; A. U. Wells

Endpoints for clinical trials of sarcoidosis

Robert P. Baughmann, M. Drent, D. A. Culver, J. C. Grutiers, T. Handa, M. Humbert, M. A. Judson, E. E. Lower, J. Mana, C. A. Pereira, A. Prasse, R. Sulica, D. Valyere, V. Vucinic, A. U. Wells

Research output: Contribution to journal › Article › peer-review

80 Scopus citations

Abstract

Over the past few years an increasing number of prospective controlled sarcoidosis treatment trials have been completed. Unfortunately, these studies utilize different endpoints making comparisons between studies difficult. At the recent World Association of Sarcoidosis and other Granulomatous disease (WASOG) meeting, a session was dedicated to the evaluation of clinical endpoints for various disease manifestations. These included pulmonary, pulmonary hypertension, fatigue, cutaneous, and a classification of clinical disease phenotypes. Based on the available literature and our current understanding of the disease, recommendations for clinical evaluation were proposed for each disease category. For example, it was recommended that pulmonary studies should include changes in the forced vital capacity. Additionally, it was recommended that all trials should incorporate measurement of quality of life.

Original language	English
Pages (from-to)	90-98
Number of pages	9
Journal	Sarcoidosis Vasculitis and Diffuse Lung Diseases
Volume	29
Issue number	2
State	Published - 2012
Externally published	Yes

Keywords

Fatigue assessment scale
Forced vital capacity
Quality of life
Scadding stage
Short form 36

Cite this

@article{e98452b2e0a64a8cae427a8019ddfdad,

title = "Endpoints for clinical trials of sarcoidosis",

abstract = "Over the past few years an increasing number of prospective controlled sarcoidosis treatment trials have been completed. Unfortunately, these studies utilize different endpoints making comparisons between studies difficult. At the recent World Association of Sarcoidosis and other Granulomatous disease (WASOG) meeting, a session was dedicated to the evaluation of clinical endpoints for various disease manifestations. These included pulmonary, pulmonary hypertension, fatigue, cutaneous, and a classification of clinical disease phenotypes. Based on the available literature and our current understanding of the disease, recommendations for clinical evaluation were proposed for each disease category. For example, it was recommended that pulmonary studies should include changes in the forced vital capacity. Additionally, it was recommended that all trials should incorporate measurement of quality of life.",

keywords = "Fatigue assessment scale, Forced vital capacity, Quality of life, Scadding stage, Short form 36",

author = "Baughmann, {Robert P.} and M. Drent and Culver, {D. A.} and Grutiers, {J. C.} and T. Handa and M. Humbert and Judson, {M. A.} and Lower, {E. E.} and J. Mana and Pereira, {C. A.} and A. Prasse and R. Sulica and D. Valyere and V. Vucinic and Wells, {A. U.}",

year = "2012",

language = "English",

volume = "29",

pages = "90--98",

journal = "Sarcoidosis Vasculitis and Diffuse Lung Diseases",

issn = "1124-0490",

publisher = "Mattioli 1885",

number = "2",

}

TY - JOUR

T1 - Endpoints for clinical trials of sarcoidosis

AU - Baughmann, Robert P.

AU - Drent, M.

AU - Culver, D. A.

AU - Grutiers, J. C.

AU - Handa, T.

AU - Humbert, M.

AU - Judson, M. A.

AU - Lower, E. E.

AU - Mana, J.

AU - Pereira, C. A.

AU - Prasse, A.

AU - Sulica, R.

AU - Valyere, D.

AU - Vucinic, V.

AU - Wells, A. U.

PY - 2012

Y1 - 2012

N2 - Over the past few years an increasing number of prospective controlled sarcoidosis treatment trials have been completed. Unfortunately, these studies utilize different endpoints making comparisons between studies difficult. At the recent World Association of Sarcoidosis and other Granulomatous disease (WASOG) meeting, a session was dedicated to the evaluation of clinical endpoints for various disease manifestations. These included pulmonary, pulmonary hypertension, fatigue, cutaneous, and a classification of clinical disease phenotypes. Based on the available literature and our current understanding of the disease, recommendations for clinical evaluation were proposed for each disease category. For example, it was recommended that pulmonary studies should include changes in the forced vital capacity. Additionally, it was recommended that all trials should incorporate measurement of quality of life.

AB - Over the past few years an increasing number of prospective controlled sarcoidosis treatment trials have been completed. Unfortunately, these studies utilize different endpoints making comparisons between studies difficult. At the recent World Association of Sarcoidosis and other Granulomatous disease (WASOG) meeting, a session was dedicated to the evaluation of clinical endpoints for various disease manifestations. These included pulmonary, pulmonary hypertension, fatigue, cutaneous, and a classification of clinical disease phenotypes. Based on the available literature and our current understanding of the disease, recommendations for clinical evaluation were proposed for each disease category. For example, it was recommended that pulmonary studies should include changes in the forced vital capacity. Additionally, it was recommended that all trials should incorporate measurement of quality of life.

KW - Fatigue assessment scale

KW - Forced vital capacity

KW - Quality of life

KW - Scadding stage

KW - Short form 36

UR - http://www.scopus.com/inward/record.url?scp=84872313151&partnerID=8YFLogxK

M3 - Article

C2 - 23461070

AN - SCOPUS:84872313151

SN - 1124-0490

VL - 29

SP - 90

EP - 98

JO - Sarcoidosis Vasculitis and Diffuse Lung Diseases

JF - Sarcoidosis Vasculitis and Diffuse Lung Diseases

IS - 2

ER -

Endpoints for clinical trials of sarcoidosis

Abstract

Keywords

Fingerprint

Cite this